Breast Cancer, Hot Flashes, Postmenopausal Symptoms
Conditions
Keywords
Hot Flashes, Postmenopausal Symptoms, Hypnotic Relaxation Therapy, Mind Body, Hypnosis
Brief summary
The long-term goal of this program of research is to determine safe and effective non-hormonal interventions for menopausal symptoms. The main goal of this study is to evaluate whether self-administered hypnosis can be used to significantly reduce hot flashes more than self-administered white noise hypnosis over 6 weeks of home practice. The investigators are also examining the impact of each hypnosis group on sleep, anxiety, perceived and measured stress, heart rate variability, and daily activities.
Detailed description
This randomized, two arm clinical trial will evaluate the efficacy of self-administered hypnosis for the treatment of hot flashes in postmenopausal women using a 1:1 randomization schedule. Primary Objective To evaluate the efficacy of the self-administered hypnosis intervention for hot flashes compared to the self-administered white noise hypnosis. Hypothesis 1: Self-administered hypnosis will significantly decrease vasomotor symptoms (hot flash score of frequency and severity) compared to the self-administered white noise hypnosis at 6 weeks. Secondary Objectives To evaluate the efficacy of the self-administered hypnosis compared to self-administered white noise hypnosis for hot flash activity interference, sleep disturbance, anxiety and perception of benefit; with the expectation that there will be significant improvements among participants in the self-administered hypnosis group when compared with the self-administered white noise hypnosis group at 6 weeks. The investigators will also evaluate the effects of self-administered hypnosis compared to the self-administered white noise hypnosis at 12 weeks for all secondary outcomes except perception of benefit. Additionally, mediators (perceived stress, cortisol, and heart rate variability (HRV)) and moderators (hypnotizability and practice adherence) of hot flash reduction will be explored. Hypothesis 2.1: Compared to self-administered white noise hypnosis, the self-administered hypnosis intervention will result in significant improvements in hot flash activity interference, sleep disturbance, and anxiety at 6 and 12 weeks, and perception of benefit at 6 weeks. Hypothesis 2.2 A decrease in perceived stress will be indicated in the self-administered hypnosis group due to the intervention, which will correspond and contribute to further decrease of the hot flash score at 6 and 12 weeks. Hypothesis 2.3 Diurnal salivary cortisol will demonstrate better circadian rhythms (steeper slopes) in those with larger hot flash reductions and in the self-administered hypnosis group compared to participants in the self-administered white noise hypnosis at 6 weeks. Hypothesis 2.4 Self-administration of hypnosis and greater hot flash reductions will result in higher resting and 24-hour parasympathetic activity, reflected as higher HRV at 6 weeks. Hypothesis 2.5 Higher hypnotizability scores and better adherence rates will be associated with greater reductions in hot flash scores in the self-administered hypnosis group. Hypothesis 2.6 Self-administered hypnosis will significantly decrease vasomotor symptoms (hot flash score of frequency and severity) compared to the self-administered white noise hypnosis at 12 weeks. Recruitment Plan Potential participants will be identified in three ways: postcard mailings and invitation letters; physician referrals and IRB approved chart screening; and flyers, advertisements and press releases. Physician referrals will come primarily from cancer centers at University of Michigan Cancer Center Breast Clinic in Ann Arbor, MI, and the Baylor Scott & White Health Center in Waco, TX. At Michigan, key eligibility criteria will be used to identify potential eligible women through the Honest Broker Office. Charts will be further screened, with IRB approval, for eligibility. If eligible, women will be sent an invitation letter where they can opt in or out of being contacted to learn more about the study. In addition, at Michigan, outreach will occur through obstetrics and gynecology, mammography, and internal medicine clinics to enable recruitment of women without a history of breast cancer. Mass mailings and local advertisement may also be used. At Baylor University, a successful and proven method of accrual has been the use of mass mailings and local advertisement (e.g. newspaper, magazines, flyers). Additionally, Dr. Elkins is a medical associate with Baylor Scott & White Health Center, which provides a direct connection with physicians and medical staff who will provide potential referrals. It is expected that each site (Baylor University and University of Michigan) will recruit approximately half of the participants. Accrual will be closely monitored and efforts to randomize an equal number at each site will be made. The study coordinators will provide education about the trial and a consent form for review both by phone and at the baseline/consent session. All other education beyond the baseline data collection will be provided at the second session 7-30 days later. Both sessions will be between 45-60 minutes. Sessions will be held at Dr. Barton's and Dr. Elkin's research offices, which each provide privacy, a recliner, a relaxing environment, and convenient parking.
Interventions
Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.
Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.
Sponsors
Study design
Intervention model description
Participants will be randomized and either be assigned to the self-hypnosis group or a self-administered white noise hypnosis group.
Eligibility
Inclusion criteria
Postmenopausal as defined by one of the following criteria: * No menstrual period in the past 12 months * Chemical menopause (LHRH antagonists) * Surgical Menopause (bilateral oophorectomy) * Evidence of menopause status per FSH and estradiol levels per institutional guidelines. Self-reported history of a minimum of 4 hot flashes per day or 28 hot flashes per week at baseline. Age over 18 years and able to give consent for participation in the study. Have discontinued other putative therapies for hot flashes for at least one month prior to enrollment (Vitamin E will be allowed) Women with a diagnosis of DCIS or invasive breast cancer stages 0-III are allowed to participate and may be on endocrine therapy of any kind. If on endocrine therapy, women must be on it for 4 weeks and not expected to stop it during the study. If not on endocrine therapy, participants should not be planning to start during the course of the study. However, unexpected treatment will not require study withdrawal but will be recorded and considered in the analysis.
Exclusion criteria
* Currently receiving other simultaneous treatment for hot flashes (antidepressant use is allowed if being used for mood alterations and participant has been on the antidepressant for at least 3 months with no plans to change dose or antidepressant during this study) * Diagnosis of clinical depression or acute anxiety disorder * Currently using any Complementary and Alternative Medicine (CAM) treatments for vasomotor symptoms. (This would include soy products and other phytoestrogens, black cohosh, and any mind-body techniques including meditation, yoga, etc.). If any therapies are used for reasons other than hot flashes and hot flash frequency meets inclusion criteria, then woman is eligible) * Diagnosis of a serious psychological illness, specifically psychoses, schizophrenia or borderline personality disorder * Currently using hypnosis for any reason * PHQ-4 score ≥ 9 * Non-English speaking * Women with stage IV breast cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hot Flash Daily Diary | The hot flash daily diary was collected at baseline (week 0), endpoint (week 6) and follow-up (week 12). | Participants completed the Hot Flash Daily Diary (Sloan et al., 2001) every day for 6 weeks to measure the daily frequency and severity (mild, moderate, severe, and very severe) of hot flashes. A total hot flash score was calculated for each participant (product of frequency x severity) after severity ratings were assigned a point value as follows: * mild = 1 * moderate = 2 * severe = 3 * very severe = 4 The hot flash score was then calculated by multiplying the participants' frequency and severity ratings of hot flashes, divided by the total number of days. A lower score indicates less frequent and/or severe hot flashes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hot Flash Related Daily Interference Scale | The Hot Flash Related Daily Interference Scale was completed at Baseline (week 0), at endpoint (week 6) and at follow-up (week 12). | This is a 10-item scale that measures hot flash interference. The Hot Flash Related Daily Interference Scale asks respondents to rate the degree on a 0 (not at all) - 10 (very much so) scale that the hot flashes interfere with various daily activities as well as overall enjoyment or quality of life. The total score will range from 0-100. The higher the total score, the more likely hot flashes are interfering with the daily activities.This measure has been shown to be valid and internally consistent with Cronbach's alpha of .96. |
| Emotional Distress Anxiety Scale | Baseline, 6 & 12 Weeks | This 29-item scale measures 5 domains of anxiety: 1) affective, 2)cognitive, 3) somatic, 4) behavioral, and 5) need for treatment. Items are scored on a scale from 1 (never) - 5 (always) with higher scores reflecting more severe anxiety. The total range for this scale is 0-145. This scale has shown excellent convergent and discriminate validity with other measures with a Cronbach's alpha .95. |
| Subject Global Impression of Change | The Subject Global Impressions of Change will be completed only at 6 weeks. | Participants were asked to fill out the Subject Global Impressions of Change at endpoint (week 6) to gauge participants' perceived benefit. The Subject Global Impression of Change is a single item in which the participant rates, from 0 to 4, the change in hot flashes since beginning the study. Response options range from not at all (0), a little (1), somewhat (2), quite a bit (3), totally satisfied (4). The question used was, How satisfied are you with the impact of the study treatment on your hot flashes?. This question has been used extensively for determination of minimally clinically significant differences in numerous oncology clinical trials prior to this study. |
| Perceived Stress Scale | Baseline, 6, & 12 weeks | This is a 10-item scale that measures the degree to which situations in one's life are appraised as stressful. The scale provides the degree to which individuals find their lives to be unpredictable, uncontrollable, and overloaded, as well as measures the current levels of experienced stress. Items are scored on a scale from 0 (never) - 4(very often) for a total score ranging from 0-40. with higher scores reflecting more perceived stress. This measure has been shown to be valid and internally consistent, with an alpha of .83. |
| Pittsburgh Sleep Quality Index | Baseline, 6, & 12 weeks. | This is a 19-item self-report inventory designed to measure sleep disturbance. The 19 items are grouped into 7 sub-scales: 1) sleep quality; 2) sleep efficiency; 3) daytime dysfunction; 4) sleep latency; 5) sleep disturbances; 6) sleep duration; and 7) use of sleep medication.These seven sub-scales are scored on a scale of 0 (better) - 3 (worse) with higher scores indicating greater sleep pathology. The sub-scales are then added for a combined total score ranging from 0 (better) - 21 (worse). Alphas for the Pittsburgh Sleep Quality Index range from .70 to .80. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Self-Hypnosis Practice Log | The practice log was completed daily by the participants and submitted to the interventionists at the end of each week throughout the study's duration (weeks one through six) and at follow-up (week 12). | Participants in both groups were given the Self-Hypnosis Practice Log to record daily practice of self-hypnosis or sham hypnosis throughout the 6-week intervention period and at the week 12 follow-up as a measure of intervention adherence. Adherence scores (number of practices per week) were calculated as the total frequency of reported practices according to group assignment in a seven-day period with or without the aid of an audio recording. Average adherence was calculated by averaging the adherence scores of week 1(initiation of study), week 6 (end of intervention), and week 12 (follow-up). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Self-Administered Hypnosis Self-administered hypnosis will be practiced daily using different audio recordings using the researcher's voice. Participants will practice hypnosis at home after completing the two study sessions.
Self-Administered Hypnosis: Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options. | 126 |
| Self-Administered White Noise Sham Hypnosis Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the two consent and education sessions.
Self-Administered White Noise Hypnosis: Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options. | 124 |
| Total | 250 |
Baseline characteristics
| Characteristic | Self-Administered Hypnosis | Self-Administered White Noise Sham Hypnosis | Total |
|---|---|---|---|
| Age, Continuous | 55.69 years STANDARD_DEVIATION 6.67 | 56.17 years STANDARD_DEVIATION 7.17 | 55.9 years STANDARD_DEVIATION 6.9 |
| Breast Cancer Survivor | 33 Participants | 29 Participants | 62 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 7 Participants | 8 Participants | 15 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 118 Participants | 115 Participants | 233 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 5 Participants | 2 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 19 Participants | 20 Participants | 39 Participants |
| Race (NIH/OMB) More than one race | 6 Participants | 7 Participants | 13 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 96 Participants | 91 Participants | 187 Participants |
| Region of Enrollment United States | 126 participants | 124 participants | 250 participants |
| Sex: Female, Male Female | 126 Participants | 124 Participants | 250 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 126 | 0 / 124 |
| other Total, other adverse events | 4 / 126 | 5 / 124 |
| serious Total, serious adverse events | 0 / 126 | 0 / 124 |
Outcome results
Hot Flash Daily Diary
Participants completed the Hot Flash Daily Diary (Sloan et al., 2001) every day for 6 weeks to measure the daily frequency and severity (mild, moderate, severe, and very severe) of hot flashes. A total hot flash score was calculated for each participant (product of frequency x severity) after severity ratings were assigned a point value as follows: * mild = 1 * moderate = 2 * severe = 3 * very severe = 4 The hot flash score was then calculated by multiplying the participants' frequency and severity ratings of hot flashes, divided by the total number of days. A lower score indicates less frequent and/or severe hot flashes.
Time frame: The hot flash daily diary was collected at baseline (week 0), endpoint (week 6) and follow-up (week 12).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Self-Administered Hypnosis | Hot Flash Daily Diary | Baseline (Week 0) | 88.7 Hot Flash Score | Standard Deviation 61.3 |
| Self-Administered Hypnosis | Hot Flash Daily Diary | Endpoint (Week 6) | 41.3 Hot Flash Score | Standard Deviation 50.8 |
| Self-Administered Hypnosis | Hot Flash Daily Diary | Follow-up (Week 12) | 34.7 Hot Flash Score | Standard Deviation 34.4 |
| Self-Administered Sham Hypnosis | Hot Flash Daily Diary | Baseline (Week 0) | 94.6 Hot Flash Score | Standard Deviation 81.6 |
| Self-Administered Sham Hypnosis | Hot Flash Daily Diary | Endpoint (Week 6) | 55.9 Hot Flash Score | Standard Deviation 50.9 |
| Self-Administered Sham Hypnosis | Hot Flash Daily Diary | Follow-up (Week 12) | 52.8 Hot Flash Score | Standard Deviation 49.4 |
Emotional Distress Anxiety Scale
This 29-item scale measures 5 domains of anxiety: 1) affective, 2)cognitive, 3) somatic, 4) behavioral, and 5) need for treatment. Items are scored on a scale from 1 (never) - 5 (always) with higher scores reflecting more severe anxiety. The total range for this scale is 0-145. This scale has shown excellent convergent and discriminate validity with other measures with a Cronbach's alpha .95.
Time frame: Baseline, 6 & 12 Weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Self-Administered Hypnosis | Emotional Distress Anxiety Scale | Baseline | 49.83 units on a scale | Standard Deviation 16.19 |
| Self-Administered Hypnosis | Emotional Distress Anxiety Scale | Endpoint | 45.93 units on a scale | Standard Deviation 15.05 |
| Self-Administered Hypnosis | Emotional Distress Anxiety Scale | Follow-up | 44.85 units on a scale | Standard Deviation 16.6 |
| Self-Administered Sham Hypnosis | Emotional Distress Anxiety Scale | Baseline | 50.82 units on a scale | Standard Deviation 16.98 |
| Self-Administered Sham Hypnosis | Emotional Distress Anxiety Scale | Endpoint | 47.59 units on a scale | Standard Deviation 16.74 |
| Self-Administered Sham Hypnosis | Emotional Distress Anxiety Scale | Follow-up | 47.79 units on a scale | Standard Deviation 16.77 |
Hot Flash Related Daily Interference Scale
This is a 10-item scale that measures hot flash interference. The Hot Flash Related Daily Interference Scale asks respondents to rate the degree on a 0 (not at all) - 10 (very much so) scale that the hot flashes interfere with various daily activities as well as overall enjoyment or quality of life. The total score will range from 0-100. The higher the total score, the more likely hot flashes are interfering with the daily activities.This measure has been shown to be valid and internally consistent with Cronbach's alpha of .96.
Time frame: The Hot Flash Related Daily Interference Scale was completed at Baseline (week 0), at endpoint (week 6) and at follow-up (week 12).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Self-Administered Hypnosis | Hot Flash Related Daily Interference Scale | Baseline | 49.3 score on a scale | Standard Deviation 22.6 |
| Self-Administered Hypnosis | Hot Flash Related Daily Interference Scale | Endpoint | 25 score on a scale | Standard Deviation 22.4 |
| Self-Administered Hypnosis | Hot Flash Related Daily Interference Scale | Follow-up | 21.4 score on a scale | Standard Deviation 20.2 |
| Self-Administered Sham Hypnosis | Hot Flash Related Daily Interference Scale | Baseline | 47.3 score on a scale | Standard Deviation 22.4 |
| Self-Administered Sham Hypnosis | Hot Flash Related Daily Interference Scale | Endpoint | 29.6 score on a scale | Standard Deviation 22 |
| Self-Administered Sham Hypnosis | Hot Flash Related Daily Interference Scale | Follow-up | 24.2 score on a scale | Standard Deviation 20.3 |
Perceived Stress Scale
This is a 10-item scale that measures the degree to which situations in one's life are appraised as stressful. The scale provides the degree to which individuals find their lives to be unpredictable, uncontrollable, and overloaded, as well as measures the current levels of experienced stress. Items are scored on a scale from 0 (never) - 4(very often) for a total score ranging from 0-40. with higher scores reflecting more perceived stress. This measure has been shown to be valid and internally consistent, with an alpha of .83.
Time frame: Baseline, 6, & 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Self-Administered Hypnosis | Perceived Stress Scale | Baseline | 12.38 units on a scale | Standard Deviation 6.686 |
| Self-Administered Hypnosis | Perceived Stress Scale | Week 6 | 11.36 units on a scale | Standard Deviation 6.368 |
| Self-Administered Hypnosis | Perceived Stress Scale | Week 12 | 10.26 units on a scale | Standard Deviation 6.123 |
| Self-Administered Sham Hypnosis | Perceived Stress Scale | Baseline | 12.11 units on a scale | Standard Deviation 6.647 |
| Self-Administered Sham Hypnosis | Perceived Stress Scale | Week 6 | 11.16 units on a scale | Standard Deviation 6.874 |
| Self-Administered Sham Hypnosis | Perceived Stress Scale | Week 12 | 10.64 units on a scale | Standard Deviation 6.935 |
Pittsburgh Sleep Quality Index
This is a 19-item self-report inventory designed to measure sleep disturbance. The 19 items are grouped into 7 sub-scales: 1) sleep quality; 2) sleep efficiency; 3) daytime dysfunction; 4) sleep latency; 5) sleep disturbances; 6) sleep duration; and 7) use of sleep medication.These seven sub-scales are scored on a scale of 0 (better) - 3 (worse) with higher scores indicating greater sleep pathology. The sub-scales are then added for a combined total score ranging from 0 (better) - 21 (worse). Alphas for the Pittsburgh Sleep Quality Index range from .70 to .80.
Time frame: Baseline, 6, & 12 weeks.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Self-Administered Hypnosis | Pittsburgh Sleep Quality Index | Baseline | 7.08 units on a scale | Standard Deviation 2.23 |
| Self-Administered Hypnosis | Pittsburgh Sleep Quality Index | Endpoint | 6.23 units on a scale | Standard Deviation 2.53 |
| Self-Administered Hypnosis | Pittsburgh Sleep Quality Index | Follow-up | 6.33 units on a scale | Standard Deviation 2.31 |
| Self-Administered Sham Hypnosis | Pittsburgh Sleep Quality Index | Baseline | 7.13 units on a scale | Standard Deviation 2.51 |
| Self-Administered Sham Hypnosis | Pittsburgh Sleep Quality Index | Endpoint | 6.31 units on a scale | Standard Deviation 2.39 |
| Self-Administered Sham Hypnosis | Pittsburgh Sleep Quality Index | Follow-up | 6.10 units on a scale | Standard Deviation 2.15 |
Subject Global Impression of Change
Participants were asked to fill out the Subject Global Impressions of Change at endpoint (week 6) to gauge participants' perceived benefit. The Subject Global Impression of Change is a single item in which the participant rates, from 0 to 4, the change in hot flashes since beginning the study. Response options range from not at all (0), a little (1), somewhat (2), quite a bit (3), totally satisfied (4). The question used was, How satisfied are you with the impact of the study treatment on your hot flashes?. This question has been used extensively for determination of minimally clinically significant differences in numerous oncology clinical trials prior to this study.
Time frame: The Subject Global Impressions of Change will be completed only at 6 weeks.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Self-Administered Hypnosis | Subject Global Impression of Change | 1.92 Units on a Scale | Standard Deviation 1.066 |
| Self-Administered Sham Hypnosis | Subject Global Impression of Change | 1.20 Units on a Scale | Standard Deviation 1.228 |
Self-Hypnosis Practice Log
Participants in both groups were given the Self-Hypnosis Practice Log to record daily practice of self-hypnosis or sham hypnosis throughout the 6-week intervention period and at the week 12 follow-up as a measure of intervention adherence. Adherence scores (number of practices per week) were calculated as the total frequency of reported practices according to group assignment in a seven-day period with or without the aid of an audio recording. Average adherence was calculated by averaging the adherence scores of week 1(initiation of study), week 6 (end of intervention), and week 12 (follow-up).
Time frame: The practice log was completed daily by the participants and submitted to the interventionists at the end of each week throughout the study's duration (weeks one through six) and at follow-up (week 12).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Self-Administered Hypnosis | Self-Hypnosis Practice Log | Baseline | 7.4 Number of practices per week | Standard Deviation 4.4 |
| Self-Administered Hypnosis | Self-Hypnosis Practice Log | Endpoint | 10.9 Number of practices per week | Standard Deviation 6.6 |
| Self-Administered Hypnosis | Self-Hypnosis Practice Log | Follow-up | 8.3 Number of practices per week | Standard Deviation 7.2 |
| Self-Administered Sham Hypnosis | Self-Hypnosis Practice Log | Baseline | 7.6 Number of practices per week | Standard Deviation 3.4 |
| Self-Administered Sham Hypnosis | Self-Hypnosis Practice Log | Endpoint | 7.4 Number of practices per week | Standard Deviation 3.1 |
| Self-Administered Sham Hypnosis | Self-Hypnosis Practice Log | Follow-up | 5.6 Number of practices per week | Standard Deviation 5.1 |